Treatment Strategies in Cancer Care
Author Information
Author(s): Philip H. Smith
Primary Institution: St James's University Hospital
Conclusion
Many doctors are hesitant to enter clinical trials for urological cancer treatments, reflecting a lack of confidence in randomisation compared to established clinical practices.
Supporting Evidence
- Only 29% of surveyed doctors would allow themselves to be entered into clinical trials if they were patients.
- 58% of doctors felt it was reasonable to offer their patients entry into clinical trials.
- Very few patients, probably no more than 3%, are entered into clinical trials.
Takeaway
Doctors often don't want to join clinical trials for cancer treatments because they feel unsure about the random choices made in these studies.
Methodology
A survey was conducted among 227 urologists, radiation oncologists, and medical oncologists regarding their treatment preferences and willingness to participate in clinical trials.
Potential Biases
Surgeons and oncologists may have biases that affect their willingness to accept randomised trials.
Limitations
The study reflects the opinions of a specific group of medical professionals and may not represent all oncologists.
Participant Demographics
The participants included 227 urologists, radiation oncologists, and medical oncologists.
Want to read the original?
Access the complete publication on the publisher's website